A Clinical Trial to Evaluate Tegavivint in Non-Small Cell Lung Cancer
Latest Information Update: 22 Feb 2021
Price :
$35 *
At a glance
- Drugs Tegavivint (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Iterion Therapeutics
- 22 Feb 2021 New trial record